Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans
and its incidence continues to rise. Although CSCC usually display a benign clinical …

Vismodegib (Erivedge®) is the first-in-class, oral small molecule inhibitor of the Hedgehog
(Hh) pathway, abnormal activation of which is associated with basal cell carcinoma (BCC) …

Globally, basal cell carcinoma is the most commonly diagnosed cancer. While most cases
are amenable to surgery, treatment options for advanced basal cell carcinoma, including …

The Hedgehog pathway (HhP) plays an important role in normal embryonic development
and its abnormal function has been linked to a variety of neoplasms. Recently, the complex …

Opinion statement Advanced basal cell carcinoma (BCC) represents a small proportion of
BCCs that are not amenable to standard therapies due to lack of efficacy, high recurrence …

Basosquamous carcinoma (BSC), an uncommon and aggressive nonmelanoma skin cancer
exhibiting characteristics ranging from basal cell carcinoma (BCC) to squamous cell …

Keratinocyte cancers–basal and cutaneous squamous cell carcinoma (BCC, cSCC)–are the
most common forms of non-melanoma skin cancer (NMSC) and there has been a significant …

Background/Aims Locally advanced (T4 per American Joint Committee on Cancer (AJCC)
8th edition) periocular basal cell carcinoma (BCC) can lead to loss of the eye. We report the …

Basal cell carcinoma (BCC) is the most commonly diagnosed type of skin cancer. BCCs are
especially prevalent in the elderly population, given their association with cumulative sun …

Simple Summary Basosquamous carcinoma is a rare, aggressive non-melanoma skin
cancer with features that lie between those of basal cell carcinoma and squamous cell …